Needham & Company Gives Buy Rating to Medidata Solutions (MDSO)

By admin | 7 years ago

Medidata Solutions (NASDAQ: MDSO)‘s stock had its “buy” rating restated by equities researchers at Needham & Company in a report issued on Wednesday.

Medidata Solutions traded down 2.46% on Wednesday, hitting $27.70. Medidata Solutions has a 1-year low of $14.07 and a 1-year high of $29.65. The company has a market cap of $662.8 million and a price-to-earnings ratio of 17.75.

The company last announced its quarterly results on Tuesday, May 1st. It reported $0.26 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.22 EPS by $0.04. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Analysts expect that Medidata Solutions will post $0.32 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Medidata Solutions from $31.00 to $34.00 in a research note to investors on Wednesday. Separately, analysts at Raymond James (NYSE: RJF) upgraded shares of Medidata Solutions from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, April 20th.

Medidata Solutions, Inc. (Medidata) is a provider of hosted clinical development solutions. The Company’s customers include pharmaceutical, biotechnology and medical device companies, academic institutions, contract research organizations (CROs), and other organizations engaged in clinical trials.

About the author